Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Bonti Inc. (neurotoxins for aesthetic and therapeutic indications) closed a $15.5mm Series C financing round from undisclosed new and returning investors. The 2015 start-up will use the proceeds for market research and to fund continued development of lead compound EB001 (botulinum neurotoxin serotype E), including completion of an ongoing Phase II study in musculoskeletal pain and preparation for an end-of-Phase II meeting with the FDA. To date the company has brought in $36.1mm through investors including RBV Capital, City Hill Ventures, Colt Ventures, JMCR Partners, and HighLight Capital.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?